BST-236, a novel cytarabine prodrug for patients with acute leukemia unfit for standard induction: a phase 1/2a study

Zuckerman, T; Ram, R; Akria, L; Koren-Michowitz, M; Hoffman, R; Henig, I; Lavi, N; Ofran, Y; Horowitz, NA; Nudelman, O; Tavor, S; Yeganeh, S; Gengrinovitch, S; Flaishon, L; Tessler, S; Ben Yakar, R; Rowe, JM

Zuckerman, T (reprint author), Rambam Hlth Care Campus, Dept Hematol & Bone Marrow Transplantat, 8 HaAliya St, IL-3109601 Haifa, Israel.

BLOOD ADVANCES, 2019; 3 (22): 3740

Abstract

High-dose cytarabine is the backbone of acute myeloid leukemia (AML) treatment. Nevertheless, its use in older patients is considerably limited due to......

Full Text Link


Links

期刊讨论 | 中国SCI论文 | 期刊主页 | 投稿经验 | 杂志官网 | 投稿链接 | 作者需知 | PMC链接 | Pubmed全文检索